Core Insights - Ascentage Pharma presented promising results from a Phase Ib/II study of Lisaftoclax in combination with azacitidine for treating myeloid malignancies at the 67th ASH Annual Meeting, highlighting its potential to address unmet medical needs in this area [1][2][5] Company Overview - Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for cancer, with a strong pipeline that includes Lisaftoclax, Olverembatinib, and APG-5918 [12][14] Clinical Study Highlights - The study demonstrated a 31.8% overall response rate (ORR) in patients with venetoclax-resistant myeloid malignancies and an 80% ORR in newly diagnosed high-risk MDS/CMML [6][15] - The safety profile of Lisaftoclax was favorable, with no dose-limiting toxicities reported across all patient cohorts in the study [10][11] Drug Mechanism and Approval Status - Lisaftoclax is an orally administered Bcl-2 selective inhibitor that restores apoptosis in cancer cells and is already approved in China for CLL/SLL patients who have received prior systemic therapy [4][14] - The company is conducting four global registrational Phase III studies for Lisaftoclax in various indications, including CLL/SLL, AML, and MDS [4][16] Future Directions - Ascentage Pharma aims to accelerate clinical programs for Lisaftoclax to provide effective therapies for patients with myeloid malignancies, fulfilling its mission to address unmet clinical needs globally [5][11]
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances